Skip to content

Study · Systematic review · 2025

6 results

Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.

Xu Y, Ji G, Shi C, Tan Y, Wang L, Gui Y

Diabetes research and clinical practice24 Oct 2025Cited by 1 (Europe PMC)

PMID42618994 (opens in a new tab)DOI10.1016/j.diabres.2025.112954 (opens in a new tab)PepBankPUB-42618994
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than placebo in a network meta-analysis.

    In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    HbA1c mean difference
    −1.4%
    tirzepatide 15 mg vs placebo

    Source sentences

    Summary
    All once-weekly GLP-1RAs outperformed placebo in reducing HbA1c (MD: -0.66 % [-0.81 %, -0.5 %] for dulaglutide 1.5 mg to -1.4 % [-1.6 %, -1.2 %] for tirzepatide 15 mg).
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide 15 mg produced greater weight loss than other once-weekly GLP-1 receptor agonists in a network meta-analysis.

    In plain wordsIn pooled trials, tirzepatide 15 mg led to more weight loss than other once-weekly GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight loss, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Other once-weekly GLP-1 receptor agonists
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    Weight mean difference
    −8.7 not stated
    tirzepatide 15 mg vs other GLP-1RAs

    Source sentences

    Summary
    Tirzepatide 15 mg showed superior weight loss (MD: -8.7 [-10, -6.8]) and systolic blood pressure reduction (MD: -4.8 [-8.2, -1.4]) versus other GLP-1RAs, but higher nausea (OR: 6.4 [4.3, 9.6]) and diarrhea risks (OR: 3.5 [2.5, 5.2]).
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide 15 mg reduced systolic blood pressure more than other once-weekly GLP-1 receptor agonists in a network meta-analysis.

    In plain wordsIn pooled trials, tirzepatide 15 mg lowered systolic blood pressure more than other once-weekly GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure reduction, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Other once-weekly GLP-1 receptor agonists
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    Systolic blood pressure mean difference
    −4.8 not stated
    tirzepatide 15 mg vs other GLP-1RAs

    Source sentences

    Summary
    Tirzepatide 15 mg showed superior weight loss (MD: -8.7 [-10, -6.8]) and systolic blood pressure reduction (MD: -4.8 [-8.2, -1.4]) versus other GLP-1RAs, but higher nausea (OR: 6.4 [4.3, 9.6]) and diarrhea risks (OR: 3.5 [2.5, 5.2]).
  4. 04HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, tirzepatide 15 mg carried a higher nausea risk than other once-weekly GLP-1 receptor agonists in a network meta-analysis.

    In plain wordsIn pooled trials, tirzepatide 15 mg caused more nausea than other once-weekly GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    IncreaseNausea, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Other once-weekly GLP-1 receptor agonists
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    Odds ratio
    6.4 ratio
    nausea, tirzepatide 15 mg vs other GLP-1RAs

    Source sentences

    Summary
    Tirzepatide 15 mg showed superior weight loss (MD: -8.7 [-10, -6.8]) and systolic blood pressure reduction (MD: -4.8 [-8.2, -1.4]) versus other GLP-1RAs, but higher nausea (OR: 6.4 [4.3, 9.6]) and diarrhea risks (OR: 3.5 [2.5, 5.2]).
  5. 05HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, tirzepatide 15 mg carried a higher diarrhea risk than other once-weekly GLP-1 receptor agonists in a network meta-analysis.

    In plain wordsIn pooled trials, tirzepatide 15 mg caused more diarrhea than other once-weekly GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    IncreaseDiarrhea, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Other once-weekly GLP-1 receptor agonists
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    Odds ratio
    3.5 ratio
    diarrhea, tirzepatide 15 mg vs other GLP-1RAs

    Source sentences

    Summary
    Tirzepatide 15 mg showed superior weight loss (MD: -8.7 [-10, -6.8]) and systolic blood pressure reduction (MD: -4.8 [-8.2, -1.4]) versus other GLP-1RAs, but higher nausea (OR: 6.4 [4.3, 9.6]) and diarrhea risks (OR: 3.5 [2.5, 5.2]).

Studies that did not test the peptide alone1

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, all once-weekly GLP-1 receptor agonists pooled in the network, tirzepatide included, outperformed placebo in reducing HbA1c.

    In plain wordsIn pooled trials, all once-weekly GLP-1 drugs, including tirzepatide, lowered HbA1c more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c reduction with all once-weekly GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    All once-weekly GLP-1RAs outperformed placebo in reducing HbA1c (MD: -0.66 % [-0.81 %, -0.5 %] for dulaglutide 1.5 mg to -1.4 % [-1.6 %, -1.2 %] for tirzepatide 15 mg).

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.